Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 27th March 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 108, 2015
Previous Article Next Article

β-Cyclodextrin modified graphene oxide–magnetic nanocomposite for targeted delivery and pH-sensitive release of stereoisomeric anti-cancer drugs

Author affiliations

Abstract

β-Cyclodextrin modified graphene oxide–magnetic (MGC) nanocomposite as an innovative drug carrier was the first to be developed via an effective layer-by-layer-assembly method. Doxorubicin hydrochloride (DOX) and epirubicin hydrochloride (EPI) as model drugs were loaded onto the MGC via π–π stacking, hydrogen bonding and hydrophobic interactions. The MGC exhibits remarkably higher loading capacity for DOX (909.09 mg g−1) and EPI (781.25 mg g−1) than magnetic graphene oxide (MG). The release profiles of the drugs are pH-sensitive which would control the release in the acidic cytoplasm of cancer cells. Furthermore, cellular uptake using fluorescein isothiocyanate (FITC) labeled MGC proves successful internalization of MGC into the cytoplasm of MCF-7 cells. The fluorescence images demonstrate that MGC/DOX, to a certain extent, displays a more excellent delivery and superior release than MGC/EPI, due to the chiral selective function of β-cyclodextrin (β-CD). The pure MGC shows no obvious cytotoxicity while drug loaded MGC reveals significantly high potency for killing MCF-7 breast cancer cells, suggesting that multi-functionalized MGC is an efficient nanoplatform for targeted delivery and controlled release of stereoisomeric anticancer drugs for biomedical applications.

Graphical abstract: β-Cyclodextrin modified graphene oxide–magnetic nanocomposite for targeted delivery and pH-sensitive release of stereoisomeric anti-cancer drugs

Back to tab navigation

Supplementary files

Publication details

The article was received on 05 Jul 2015, accepted on 13 Oct 2015 and first published on 13 Oct 2015


Article type: Paper
DOI: 10.1039/C5RA13082D
Author version
available:
Download author version (PDF)
Citation: RSC Adv., 2015,5, 89299-89308

  •   Request permissions

    β-Cyclodextrin modified graphene oxide–magnetic nanocomposite for targeted delivery and pH-sensitive release of stereoisomeric anti-cancer drugs

    C. Wang, B. Li, W. Niu, S. Hong, B. Saif, S. Wang, C. Dong and S. Shuang, RSC Adv., 2015, 5, 89299
    DOI: 10.1039/C5RA13082D

Search articles by author

Spotlight

Advertisements